ET
VRTX icon

Equitable Trust’s Vertex Pharmaceuticals VRTX Stock Holding History

Equitable Trust’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$251K Buy
562
+66
+13% +$30.8K 0.01% 430
2025
Q4 		$225K Buy
+496
New +$214K 0.01% 421
2025
Q2 		– Sell
-521
Closed -$253K – 472
2025
Q1 		$253K Hold
521
– – 0.01% 428
2024
Q4 		$210K Sell
521
-3
-0.6% -$1.39K 0.01% 458
2024
Q3 		$244K Buy
+524
New +$252K 0.02% 418

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Equitable Trust's VRTX Position: Q1 2026 in Review

Equitable Trust increased its Vertex Pharmaceuticals (VRTX) stake by 13% in Q1 2026, buying an estimated $30.8K and bringing the position to 562 shares worth $251K. The position accounts for 0.01% of the portfolio, ranked #430.

Equitable Trust first reported a position in VRTX in Q3 2024 and has held it in 5 quarters since. The position peaked at $253K in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Equitable Trust held 562 shares of Vertex Pharmaceuticals worth $251K as of Q1 2026.
  • Equitable Trust bought 66 Vertex Pharmaceuticals shares in Q1 2026, an estimated $30.8K.
  • Vertex Pharmaceuticals made up 0.01% of Equitable Trust's portfolio in Q1 2026, its #430 holding.
  • Equitable Trust first reported a position in Vertex Pharmaceuticals in Q3 2024 and has held it in 5 quarters since.
  • Equitable Trust's Vertex Pharmaceuticals position peaked at $253K in Q1 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Equitable Trust's 13F filing for Q1 2026, filed 30 Apr 2026.